Researchers uncover new cell types involved in osteoarthritis

And the development of a new slow-release drug seeks to target them

12:53 PM

Author | Valerie Goodwin

scientists together at computer in white coats
Tristan Maerz and Knights review lab findings.

A Michigan Medicine study has identified a new potential target for treating osteoarthritis – a debilitating joint disease that affects over 31 million Americans and is a leading cause of disability worldwide.

A team of researchers led by Tristan Maerz, Ph.D., a biomedical engineer and assistant professor in the Department of Orthopaedic Surgery at Michigan Medicine has uncovered previously unknown cell types in the joint that emerge after an injury and drive the onset of osteoarthritis.

Clinically, osteoarthritis presents as a very complex disease, with patients suffering from joint stiffness, reduced mobility and function, and most notably, persistent pain.

Osteoarthritis patients commonly live with this condition for multiple decades, and no treatments have been developed that can stop or reverse the disease. The condition can occur with age or be sparked by a joint injury and is typically managed with pain relief and end-stage joint replacement.

The study “Synovial fibroblasts assume distinct functional identities and secrete R-spondin 2 in osteoarthritis” published in the Annals of the Rheumatic Diseases examined the cellular and molecular events during the onset of post-traumatic osteoarthritis in joints.

“We identified cell types that emerge in the joint after trauma, such as an ACL injury, and we can now associate these cells with the disease process,” Maerz said. “This allows us to view them as a treatment target for this devastating disease.”

By employing a cutting-edge gene sequencing technology called single-cell RNA-sequencing, Maerz and his team were able to uncover these previously uncharacterized cells that emerge in the joint after injury.

The study also described the biological processes that may activate these cells, which offers compelling new targets for an effective treatment.

“Interestingly, these cells are not found in healthy joints, and we have to understand exactly what causes them to appear and how they may cause osteoarthritis,” said Alex Knights, Ph.D., a senior post-doctoral researcher in the Maerz Laboratory, who was instrumental in uncovering and describing these cells and their biology.

Now, having identified several cell types that may be responsible for causing the disease, the Maerz Laboratory are hopeful that targeting them may be an effective osteoarthritis treatment.

“This research will further our understanding of the ways that osteoarthritis progresses, particularly after an injury to the knee,” said Elizabeth Dailey, M.D., an orthopedic surgeon treating end-stage osteoarthritis and joint replacement specialist at University of Michigan Health who is working together with Maerz and his team.

Maerz and his team are now working with biomedical specialists to develop new drug delivery systems that can be injected into joints in the aftermath of a traumatic injury to slow down or ideally halt the development of osteoarthritis.

This work will be done alongside Craig Duvall, Ph.D., a drug delivery and biomaterials engineering expert from Vanderbilt University, to create a slow-release drug to block the disease before it has a chance to take hold following joint trauma.

“This has the potential to yield a single long-lasting treatment which is necessary for patient compliance in a chronic disease like osteoarthritis. Local delivery also minimizes the possibility for side effects due to drug exposure in other tissues and organs, and it maximizes the drug benefit at the targeted disease site,” Duvall stated.

The Maerz Laboratory has been awarded a $2.5 million grant by the National Institute of Arthritis and Musculoskeletal and Skin Diseases to develop and test a biomaterial-based drug delivery system to treat osteoarthritis.

“This new study and the federal funding are a large step forward for osteoarthritis research on campus and across the country,” stated Kurt Hankenson, D.V.M., Ph.D., a senior colleague of the Maerz laboratory and the associate chair for research in the Department of Orthopaedic Surgery.

“We work closely with our surgeon colleagues to understand the clinical relevance of our laboratory research to maximize its potential impact on clinical care, which is our ultimate objective.”

This work will also seek to understand how a certain molecular signaling pathway, specifically Wnt signaling, is involved in the early activation of joint cells after injury.

“For us to be able to develop a treatment that can be given immediately after a joint injury to block this disease process gives hope for the osteoarthritis patient,” Maerz said.

Live your healthiest life: Get tips from top experts weekly. Subscribe to the Michigan Health blog newsletter

Headlines from the frontlines: The power of scientific discovery harnessed and delivered to your inbox every week. Subscribe to the Michigan Health Lab blog newsletter

Like Podcasts? Add the Michigan Medicine News Break on Spotify, Apple Podcasts or anywhere you listen to podcasts.

Paper cited: “Synovial fibroblasts assume distinct functional identities and secrete R-spondin 2 in osteoarthritis,” Annals of the Rheumatic Diseases. DOI: 10.1136/ard-2022-222773


More Articles About: All Research Topics Bones and Muscles and Joints (Orthopaedics) Joint Pain Pain management chronic pain Body Work
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories friends talking outside older walking smiling
Health Lab
Older adults’ health may get a little help from their friends 
Close friendships include help with health-related advice or support for people over 50, but those with major mental or physical health issues have fewer close friends.
navy brain on off white background with artificial intelligence lines inside with yellow highlighted areas
Health Lab
People want to know if AI is used in their health care
A study published in JAMA Network Open finds most people want to be notified if AI is used in their health care.
PURPLE BLUE RED CELLS FLOATING
Health Lab
Using cellular therapy to treat cancer, and beyond
Here, Monalisa Ghosh, M.D., a hematologist-oncologist at the University of Michigan Health Rogel Cancer Center, answers questions about cellular therapy; how it's used and what exciting developments are soon to come.
sketched out bacteria in a dish yellow and blue colors of U-M
Health Lab
More clues reveal how gut bacteria works
Research from the University of Michigan uncovers a unique way the bacteria Bacteroides, which make up nearly half of the gut microbiome, synthesize the proteins needed to degrade carbohydrates.
yellow tinted graphic moving with mouth opening seeing down throat red and tonsils in pink in back
Health Lab
Study finds tonsil removal not linked to undesirable weight gain, contrary to popular belief
A trial involving Michigan Medicine researchers has upended a long-held belief that adenotonsillectomies for children with mild sleep-disordered breathing lead to undesirable weight gain.
bone close up of cells inside green bbble with cells inside in yellow brown pink and red orange background
Health Lab
How breast cancer cells survive in bone marrow after remission
A new study from researchers at the University of Michigan and the University of California San Diego has shed light on a previously poorly understood aspect of breast cancer recurrence: how cancer cells survive in bone marrow despite targeted therapies.